Related Experiment Videos
Deferoxamine posttreatment reduces ischemic brain injury in neonatal rats
C Palmer1, R L Roberts, C Bero
1Department of Pediatrics, Milton S. Hershey Medical Center, Pennsylvania State University, Hershey 17033.
Insights
Deferoxamine, an iron chelator, significantly reduced brain injury in newborn rats after hypoxic-ischemic events. This iron chelation therapy shows promise for protecting vulnerable neonatal brains from damage.
Area of Science:
- Neuroscience
- Neonatal Research
- Pharmacology
Background:
- Iron overload exacerbates brain damage during reperfusion after hypoxia-ischemia.
- Neonatal brains, with high iron concentrations at birth, are particularly susceptible to iron-dependent injury.
- The ferric iron chelator deferoxamine was investigated for its neuroprotective potential in neonatal hypoxic-ischemic brain injury.
Purpose of the Study:
- To determine if deferoxamine administration can mitigate hypoxic-ischemic brain injury in neonatal rats.
- To measure brain deferoxamine levels and pharmacokinetic parameters.
- To explore potential mechanisms of action, considering deferoxamine's concentration-dependent effects.
Main Methods:
- Hypoxic-ischemic brain injury was induced in 7-day-old rats via carotid artery ligation and hypoxia.
- Deferoxamine mesylate (100 mg/kg) or saline was administered subcutaneously 5 minutes post-hypoxia.
- Brain injury was assessed by measuring hemispheric water content (early edema) and hemisphere atrophy (late).
- Brain and serum deferoxamine levels were measured post-treatment.
Main Results:
- Deferoxamine significantly reduced early brain edema (water content, P < .01) and late hemisphere atrophy (P = .019).
- Brain deferoxamine concentrations peaked at 100–200 µmol/L between 40–60 minutes post-injection, exceeding serum levels.
- These findings suggest deferoxamine effectively penetrates the neonatal brain.
Conclusions:
- Post-hypoxic-ischemic deferoxamine administration effectively reduces brain injury in neonatal rats.
- Achieved brain concentrations of deferoxamine may exert protective effects through mechanisms beyond simple iron chelation.
- Deferoxamine represents a potential therapeutic agent for neonatal hypoxic-ischemic brain injury.
Background And Purpose:
Iron catalyzes the formation of damaging reactive species during cerebral reperfusion. Brain iron concentration is highest at birth, so the brain of the asphyxiated newborn may be at increased risk of iron-dependent injury. We investigated whether the ferric iron chelator deferoxamine could reduce hypoxic-ischemic brain injury in neonatal rats. Because deferoxamine has concentration-dependent activities other than iron chelation, we measured brain deferoxamine levels and calculated deferoxamine pharmacokinetic parameters.
Methods:
We produced hypoxic-ischemic injury to the right cerebral hemisphere of 7-day-old rats by right common carotid artery ligation followed by 2.25 hours of hypoxia in 8% oxygen. At 5 minutes of recovery from hypoxia the rats received 100 mg/kg deferoxamine mesylate or saline subcutaneously. Rats (saline, n = 33; deferoxamine, n = 38) were killed at 42 hours of recovery to assess early acute edema by measurement of hemispheric water content. Other rats (saline, n = 31; deferoxamine, n = 32) were killed at 30 days of age for morphometric determination of right hemisphere atrophy. In still other rats, we measured deferoxamine levels in blood and brain after hypoxia-ischemia.
Results:
Deferoxamine significantly reduced right hemisphere injury as measured by early water content (P < .01) and later atrophy (P = .019). Deferoxamine brain levels peaked between 100 and 200 mumol/L at 40 to 60 minutes after injection and exceeded serum levels by +/- 70%.
Conclusions:
Deferoxamine administered after induction of cerebral hypoxia-ischemia reduces injury in 7-day-old rats. Deferoxamine concentrates in the brain at levels between 100 and 200 mumol/L. At the concentrations achieved, deferoxamine might protect the brain through mechanisms unrelated to its ability to chelate iron.